We use cookies for a better user experience. Read our Privacy Policy

I Agree

Preimplantation Genetic Diagnosis Market

Preimplantation Genetic Diagnosis Market (Test Type - PGD for Chromosomal Aberrations, Aneuploidy Screening, Gender Selection, Single Gene Disorders, HLA Typing and X-linked Diseases) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

Preimplantation genetic diagnosis is also called as embryo screening. It is a branch of genetics that consists of genetic testing of embryo with the help of in-vitro fertilization. Preimplantation genetic diagnosis helps in cutting down the risk of selective pregnancy termination for those couples how carry a considerable risk of transferring major genetic disorders or chromosomal or hereditary diseases such as cystic fibrosis and spinal muscular atrophy.

The global market for preimplantation genetic diagnosis is expected to witness a promising rate of growth in coming years of the forecast period because of the growing prevalence of these genetic and hereditary disorders. In addition to this, preimplantation genetic diagnosis has more chances of conceiving a healthier embryo. Naturally, the people with such risks are inclined towards using this treatment for creating healthier and risk free embryo.

Recent technological developments and advancements have considerably changed the traditional practices of parental screening. It has helped in early detection of any possible genetic disorder and thus prevent it from passing through to the offspring. This too has been a key driving factor for the overall growth of the global preimplantation genetic diagnosis market.

However, there are some factors that might impede the growth of the global market for preimplantation genetic diagnosis. One of the biggest cause of concern is the high cost associated with these diagnostic test. This has made it almost impossible for population with lower income to undergo such tests and have a healthy offspring. In addition to this, in some countries there are ethical and governmental restrictions on carrying out such diagnostic tests. This too is expected to hamper the growth of the market.

However, with increasing technological developments, urbanization, and healthcare awareness, it is expected that people will undergo preimplantation genetic diagnosis so as to avoid the risk of passing non-curable genetic diseases to their child.

Since the last two decades, preimplantation genetic diagnosis (PGD) has been used to detect chromosomal aneuploidy in low prognosis patients who undergo in-vitro fertilization (IVF). PGD is now being used to detect a broader range of indications due to advancements in the medical technology. These indications include chromosomal aberrations, genetic abnormalities, gender selection, HLA typing, X-linked diseases and single gene diseases. Demand for PGD is continuously increasing in patients who undergo IVF in the hope that it would improve the probability of live birth and reduce the chances of disabilities and genetic disorders in the offspring. 

Preimplantation genetic diagnosis (PGD) is an adjuvant technique to in vitro fertilization (IVF) for detecting genetic diseases or conditions before the implantation of embryo. PGD can be performed for screening of a range of medical conditions such as Down’s syndrome, inheritable diseases and traits of other physiological abnormality. Increasing patient awareness about PGD technique and rising prevalence of genetic disorders among infants has led to the rise in demand for PGD along with IVF procedure. The combination of PGD and IVF  has improved the rate of successful pregnancy due to reduced chances of passing the undesired genetic material in the embryo.

The use of array comparative genomic hybridization (aCGH) and fluorescent in situ hybridization (FISH) techniques in PGD has improved the process efficiency and success rate of pregnancy through IVF. Demand for PGD, however, is dependent on the regulations governing infertility procedures in various countries. PGD for gender selection and HLA typing is banned in most parts of Asia, whereas it is regulated in the U.S. and in some parts of the European Union. Regulatory impact plays a major role in analyzing the global preimplantation genetic diagnosis market.

Based on the type of test, the global preimplantation genetic diagnosis market has been categorized into six segments: PGD for chromosomal aberrations, PGD for aneuploidy screening, PGD for gender selection, PGD for single gene disorder, PDG for HLA typing and PGD for X-linked diseases. PGD for aneuploidy screening held the highest share in 2013 as aneuploidy could lead to severe abnormalities. Aneuploidy screening reduces the probability of transferring an embryo with chromosomal abnormality. . Aneuploidy screening during prenatal testing has a major disadvantage; if the chromosomal abnormality were detected in the fetus, the pregnancy would be terminated. However, this drawback is efficiently overcome by opting for preimplantation genetic diagnosis, since genetic screening for aneuploidy is performed before the embryo is implanted and pregnancy is conceived.

Geographically, the global preimplantation genetic diagnosis market has been categorized into four regions: North America, Europe, Asia Pacific and Rest of the World (RoW). Each geographical market has been further analyzed based on the types of test. Europe dominated the global preimplantation genetic diagnosis market in 2013 due to increasing patient awareness and high number of IVF cycles being performed in the region. Conversely, North America is expected to grow at a higher CAGR during the forecast period due to rapid increase in the number of IVF cycles being performed and the rising disability rate due to increase in smoking. Moreover, high cost of the gender selection procedure and rising demand for identifying and selecting the gender by mothers increases the market share of PGD in gender selection. Restrictions on gender selection and detection of X-linked diseases in developing regions such as Asia Pacific, Latin America and Africa restrain the growth of the PGD market. Moreover, lack of patient awareness and inadequate healthcare facilities in the developing economies of these regions limit the use of PGD in HLA typing and detection of single gene disorder.

The global preimplantation genetic diagnosis market is characterized by the presence of some of the major companies including Genesis Genetics, Genea Ltd., Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc., PerkinElmer, Inc., Quest Diagnostics, Inc., Reprogenetics LLC and Reproductive Genetics Institute. Market players are in constant endeavor to improve their technologies in genetic testing in order to enhance the efficiency and provide better services to healthcare practitioners.
Preimplantation Genetic Diagnosis Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

 
Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.4 Research Methodology
1.5 List of Abbreviations
 
Chapter 2 Executive Summary
2.1 Market Snapshot: Global Preimplantation Genetic Diagnosis Market
2.2 Comparative Analysis: Global Preimplantation Genetic Diagnosis Market, by Geography, 2013 & 2020 (Value %)
 
Chapter 3 Global Preimplantation Genetic Diagnosis Market Overview
3.1 Introduction
     3.1.1 Preimplantation Genetic Diagnosis Process
     3.1.2 Preimplantation Genetic Diagnosis Applications
3.2 Market Dynamics
     3.2.1 Market Drivers
             3.2.1.1 Delay in conception results in increased demand of PGD among higher age women
             3.2.1.2 Increasing incidence rates of genetic diseases influencing patients to undergo PGD cycles for disease free offspring
             3.2.1.3 Lifestyle hazards such as smoking, stress and pollution are leading to decreased fertility resulting in increased demand for IVF and PGD
     3.2.2 Market Restraints
             3.2.2.1 Economic and social factors associated with IVF restrains the PGD market
             3.2.2.2 Limited insurance coverage for IVF and PGD results in less patient pool
     3.2.3 Market Opportunities
             3.2.3.1 Innovation in cancer prevention will increase the demand for PGD during forecast period
             3.2.3.2 Advancement in the field of genetics will propel the growth of PGD market
3.3 Regulatory Framework: Preimplantation Genetic Diagnosis
3.4 Porter’s Five Forces Analysis for the Global Preimplantation Genetic Diagnosis Market
     3.4.1 Bargaining Power of Suppliers
     3.4.2 Bargaining Power of Buyers
     3.4.3 Threat of New Entrants
     3.4.4 Threat of Substitutes
     3.4.5 Competitive Rivalry
3.5 Market Attractiveness Analysis: Global Preimplantation Genetic Diagnosis Market, by Geography
3.6 Competitive Landscape
     3.6.1 Heat Map Analysis for Key Market Players of Global Preimplantation Genetic Diagnosis Market
 
Chapter 4 Global Preimplantation Genetic Diagnosis Market, by Test Type
4.1 Overview
     4.1.1 Global Preimplantation Genetic Diagnosis Market Revenue, by Test Type, 2012 – 2020 (USD Million)
4.2 Comparative Analysis: Global Preimplantation Genetic Diagnosis Market, by Test Type, 2013 & 2020 (Value %)
4.3 PGD for Chromosomal Aberrations
     4.3.1 Global PGD for Chromosomal Aberrations Market Revenue, 2012 – 2020 (USD Million)
4.4 PGD for Aneuploidy Screening
     4.4.1 Global PGD for Aneuploidy Screening Market Revenue, 2012 – 2020 (USD Million)
4.5 PGD for Gender Selection
     4.5.1 Global PGD for Gender Selection Market Revenue, 2012 – 2020 (USD Million)
4.6 PGD for Single Gene Disorder
     4.6.1 Global PGD for Single Gene Disorder Market Revenue, 2012 – 2020 (USD Million)
4.7 PGD for HLA Typing
     4.7.1 Global PGD for HLA Typing Market Revenue, 2012 – 2020 (USD Million)
4.8 PGD for X-linked diseases
     4.8.1 Global PGD for X-linked Diseases Market Revenue, 2012 – 2020 (USD Million)
 
Chapter 5 Preimplantation Genetic Diagnosis Market, by Geography
5.1 Overview
     5.1.1 Global Preimplantation Genetic Diagnosis Market Revenue, by Geography, 2012 – 2020 (USD Million)
5.2 North America
     5.2.1 North America Preimplantation Genetic Diagnosis Market Revenue, 2012 – 2020 (USD Million)
     5.2.2 North America Preimplantation Genetic Diagnosis Market Revenue, by Test Type, 2012 – 2020 (USD Million)
5.3 Europe
     5.3.1 Europe Preimplantation Genetic Diagnosis Market Revenue, 2012 – 2020 (USD Million)
     5.3.2 Europe Preimplantation Genetic Diagnosis Market Revenue, by Test Type, 2012 – 2020 (USD Million)
5.4 Asia Pacific
     5.4.1 Asia Pacific Preimplantation Genetic Diagnosis Market Revenue, 2012 – 2020 (USD Million)
     5.4.2 Asia Pacific Preimplantation Genetic Diagnosis Market Revenue, by Test Type, 2012 – 2020 (USD Million)
5.5 Rest of the World (RoW)
     5.5.1 Rest of the World Preimplantation Genetic Diagnosis Market Revenue, 2012 – 2020 (USD Million)
     5.5.2 Rest of the World Preimplantation Genetic Diagnosis Market Revenue, by Test Type, 2012 – 2020 (USD Million)
 
Chapter 6 Recommendations
6.1 Introduction of Innovative Technologies to Reduce the Cost of Equipment and Procedure
6.2 Draw from Rapidly Growing CRAMS Market in Emerging Economies
 
Chapter 7 Company Profiles
7.1 Genesis Genetics
     7.1.1 Company Overview
     7.1.2 Financial Overview
     7.1.3 Product Portfolio
     7.1.4 Business Strategies
     7.1.5 Recent Developments
7.2 Genea Ltd.
     7.2.1 Company Overview
     7.2.2 Financial Overview
     7.2.3 Product Portfolio
     7.2.4 Business Strategies
     7.2.5 Recent Developments
7.3 Illumina, Inc.
     7.3.1 Company Overview
     7.3.2 Financial Overview
     7.3.3 Product Portfolio
     7.3.4 Business Strategies
     7.3.5 Recent Developments
7.4 Laboratory Corporation of America Holdings (LabCorp)
     7.4.1 Company Overview
     7.4.2 Financial Overview
     7.4.3 Product Portfolio
     7.4.4 Business Strategies
     7.4.5 Recent Developments
7.5 Natera, Inc.
     7.5.1 Company Overview
     7.5.2 Financial Overview
     7.5.3 Product Portfolio
     7.5.4 Business Strategies
     7.5.5 Recent Developments
7.6 PerkinElmer, Inc.
     7.6.1 Company Overview
     7.6.2 Financial Overview
     7.6.3 Product Portfolio
     7.6.4 Business Strategies
     7.6.5 Recent Developments
7.7 Quest Diagnostics, Inc.
     7.7.1 Company Overview
     7.7.2 Product Portfolio
     7.7.3 Financial Overview
     7.7.4 Business Strategies
     7.7.5 Recent Developments
7.8 Reprogenetics LLC
     7.8.1 Company Overview
     7.8.2 Financial Overview
     7.8.3 Product Portfolio
     7.8.4 Business Strategies
     7.8.5 Recent Developments
7.9 Reproductive Genetics Institute
     7.9.1 Company Overview
     7.9.2 Financial Overview
     7.9.3 Product Portfolio
     7.9.4 Business Strategies
     7.9.5 Recent Developments
List of Tables
 
TABLE 1 List of Abbreviations
TABLE 1 Market Snapshot: Global Preimplantation Genetic Diagnosis Market
TABLE 2 Global Preimplantation Genetic Diagnosis Market Revenue, by Test Type, 2012 – 2020 (USD Million)
TABLE 3 Global Preimplantation Genetic Diagnosis Market Revenue, by Geography, 2012 – 2020 (USD Million)
TABLE 4 North America Preimplantation Genetic Diagnosis Market Revenue, by Test Type, 2012 – 2020 (USD Million)
TABLE 5 Europe  Preimplantation Genetic Diagnosis Market Revenue, by Test Type, 2012 – 2020 (USD Million)
TABLE 6 Asia Pacific Preimplantation Genetic Diagnosis Market Revenue, by Test Type, 2012 – 2020 (USD Million)
TABLE 7 Rest of the World Preimplantation Genetic Diagnosis Market Revenue, by Test Type, 2012 – 2020 (USD Million)

List of Figures

 

FIG. 1 Preimplantation Genetic Diagnosis Market Segmentation

FIG. 2 Global Preimplantation Genetic Diagnosis Market, by Test Type, 2013 (USD Million)

FIG. 3 Comparative Analysis: Global Preimplantation Genetic Diagnosis Market, by Geography, 2013 & 2020 (Value %)

FIG. 4 Preimplantation Genetic Diagnosis Process

FIG. 5 Porter’s Five Forces Analysis for the Global Preimplantation Genetic Diagnosis Market

FIG. 6 Market Attractiveness Analysis of the Global Preimplantation Genetic Diagnosis Market, by Geography

FIG. 7 Heat Map Analysis for Key Market Players of Global Preimplantation Genetic Diagnosis Market

FIG. 8 Comparative Analysis of the Global Preimplantation Genetic Diagnosis Market, by Test Type, 2013 & 2020 (%)

FIG. 9 Global PGD for Chromosomal Aberrations Market Revenue, 2012 – 2020 (USD Million)

FIG. 10 Global PGD for Aneuploidy Screening Market Revenue, 2012 – 2020 (USD Million)

FIG. 11 Global PGD for Gender Selection Market Revenue, 2012 – 2020 (USD Million)

FIG. 12 Global PGD for Single Gene Disorder Market Revenue, 2012 – 2020 (USD Million)

FIG. 13 Global PGD for HLA Typing Market Revenue, 2012 – 2020 (USD Million)

FIG. 14 Global PGD for X-linked Diseases Market Revenue, 2012 – 2020 (USD Million)

FIG. 15 North America Preimplantation Genetic Diagnosis Market Revenue, 2012 – 2020 (USD Million)

FIG. 16 Europe Preimplantation Genetic Diagnosis Market Revenue, 2012 – 2020 (USD Million)

FIG. 17 Asia Pacific Preimplantation Genetic Diagnosis Market Revenue, 2012 – 2020 (USD Million)

FIG. 18 Rest of the World Preimplantation Genetic Diagnosis Market Revenue, 2012 – 2020 (USD Million)

FIG. 19 Illumina, Inc.: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 20 LabCorp: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 21 PerkinElmer Inc.: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 22 Quest Diagnostics: Annual Revenue, 2011 – 2013 (USD Million)

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

363

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved